Skip to main content

Table 4 Incremental cost-effectiveness ratios (dosage 40 mg/kg/week unless otherwise specified)

From: Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease

  Costs/QALY gained Costs/life year gained
Base case analysis dosage 40 mg/kg/week € 1,043,868 € 525,873
Registered dosage regimen (20 mg/kg/2 weeks) € 286,114 € 144,137
Lower treatment costs (costs divided by 2) € 549,280 € 276,713
Shorter time horizon (5 years) € 571,701 € 92,634
Lower utility (0.49) in both cohorts € 1,304,835 € 525,873
Higher utility (0.74) in both cohorts € 869,890 € 525,873
Lower utility in ST-treated patients € 1,021,610 € 525,873
Lognormal survival distribution € 1,050,595 € 452,669
No costs incurred by ST-treated patients € 1,049,203 € 528,560
Double cost incurred by ST-treated patients € 1,031,836 € 520,387